Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP19 | O94966 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | ARG1 | P05089 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21246350 | 0.79 | USP19 (0.34) | USP19SMN1; SMN2GRM5GRM4 | |
| SCHEMBL11464909 | 0.76 | SMN1; SMN2 (0.36) | USP19SMN1; SMN2GRM5 | |
| Hydrochloric Acid SCHEMBL21224547 | 0.74 | ALOX15 (0.35) | USP19ARG1 | |
| Hydrochloric Acid SCHEMBL21224546 | 0.74 | ALOX15 (0.35) | USP19ARG1 | |
| SCHEMBL21246351 | 0.72 | GRIN2B (0.43) | USP19SMN1; SMN2GRM5 | |
| SCHEMBL21246352 | 0.72 | GRIN2B (0.43) | USP19SMN1; SMN2GRM5 | |
| SCHEMBL21246354 | 0.72 | GRIN2B (0.43) | USP19SMN1; SMN2GRM5 | |
| Hydrochloric Acid SCHEMBL21225114 | 0.71 | GRM5 (0.33) | USP19SMN1; SMN2GRM5GRM4 | |
| SCHEMBL21246333 | 0.71 | GRM5 (0.34) | USP19SMN1; SMN2GRM5 | |
| SCHEMBL20814033 | 0.69 | DPP4 (0.41) | DPP4PREPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019152688-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2019-08-08 | — | — | WO | disclosed |